Eli LillyLLY
Recorded

Eli Lilly 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 3 minParticipants24

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Eli Lilly Third Quarter 2026 Earnings Conference Call. At this time, all participants are on a listen only mode. Later, we will be conducting a question and answer session and instructions will be given at that time. Should you require operator assistance during the call, please press star, then zero and an operator will assist you offline. I would now like to turn the conference over to your host, Mike Czapar, Senior Vice President of Investor Relations. Please go ahead. Good morning.

Mike CzaparSVP of Investor Relations

Thank you for joining us for Eli Lilly and Company's Q3 2026 earnings call. I am Mike Czapar, Senior Vice President of Investor Relations.

Mike CzaparSVP of Investor Relations

Joining me on today's call are Dave Ricks, Lilly's Chair and CEO, Lucas Montarce, Chief Financial Officer, Dr. Dan Skovronsky, Chief Scientific and Product Officer, Adrienne Brown, President of Lilly Immunology, Dr. Carole Ho, President of Lilly Neuroscience, Ilya Yuffa, President of Lilly USA and Global Customer Capabilities, Jake Van Naarden, President of Lilly Oncology and Head of Business Development, Patrik Jonsson, President of Lilly International, and Ken Custer, President of Lilly Cardiometabolic Health. During this call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on slide 4. Additional information concerning factors that could cause actual results to differ is contained in our latest Form 10-K and subsequent filings with the SEC. The information we provide about our products and pipeline is for the benefit of the investment community.

Mike CzaparSVP of Investor Relations

It is not intended to be promotional or otherwise influence prescribing decisions. Our commentary will focus on our non-GAAP financial measures. Now I will turn the call over to Dave.

Dave RicksChair and CEO

Thank you, Mike. Q3 was another quarter of solid execution. We delivered strong financial results, raised our full year financial guidance, advanced our pipeline, and expanded our manufacturing footprint. Revenue grew nearly $7 billion compared to Q3 2025, and our key product revenue increased by over $6 billion. Within key products, revenue from our oncology, immunology, and neuroscience portfolio doubled versus last year. We continued the global rollout of Foundayo, launching in the U.K., Mexico, and Saudi Arabia for people with obesity, and in Mexico for people with type 2 diabetes. We achieved several key regulatory and pipeline milestones since our last call, including the U.S. approval of our new weekly insulin and new indications for Inluriyo, Jaypirca, and Mounjaro.

Dave RicksChair and CEO

As part of the Medicare GLP-1 Bridge Program, we expanded access to obesity medicines in the U.S. for approximately 20 million seniors. Since the July 1 launch, more than half a million people have filled a prescription for a Lilly Medicine through this program. We have heard positive feedback from patients and physicians about the initial implementation. Within the GLP-1 Bridge Program, the Lilly portfolio is performing well. Among new bridge patients, seven out of 10 are starting on a Lilly obesity medicine. We are encouraged to see the strong uptake of the Bridge Program and believe it has the potential to both improve outcomes for seniors and save costs for Medicare. A recently published paper from the University of Southern California's Schaeffer Center for Health Policy and Economics estimated the expansion of anti-obesity medications in Medicare could deliver over $20 billion of cumulative savings over 10 years.

Dave RicksChair and CEO

This is an encouraging indicator of the magnitude of savings the GLP-1 Bridge Program could generate. We added to our pipeline through business development this quarter, acquiring AtaiBeckley Inc. and Merida Biosciences. We also progressed our manufacturing build-out to support our long-term growth outlook. We broke ground on 2 new manufacturing facilities, a $6.5 billion facility in Houston, Texas, and a $5 billion facility in Richmond, Virginia. We distributed $1.5 billion in dividends in the third quarter and executed $400 million in share repurchases. We launched the Lilly Change the Course Commitment. Through this new initiative, we set a new goal to reach as many people in resource-limited settings who have obesity and related diseases as in high income countries prior to 2040. Lastly, we announced Patrik Jonsson, President of Lilly International, will retire at the end of 2026.

Dave RicksChair and CEO

Ilya Yuffa will expand his responsibilities to include Lilly International as part of a newly created role called President of Lilly Global Markets. I want to thank Patrik for his many contributions over a successful 36-year career at Lilly. Now I'll turn the call over to Lukas to review our Q3 results.

Lucas MontarceCFO

Thanks, Dave. As shown on slide 7, Q3 was another quarter of industry leading financial results. Revenue grew 39% compared to Q3 2025, driven by Mounjaro, Zepbound, and strong momentum across therapeutic areas and geographies. Gross margin as a percentage of revenue increased 80 basis points to 84.4%. Favorable product mix and improved cost of production were partially offset by lower realized prices. Marketing, selling, and administrative expenses increased 14% as we invested in promotional activities to support current and planned product launches.

Lucas MontarceCFO

R&D expenses increased 23%, driven by investment in our growing pipeline of early and late-stage programs and new molecules added through business development. Our non-GAAP performance margin was 54.2%, an increase of 5.9 percentage points from Q3 2025, driven by revenue growth.

Lucas MontarceCFO

Non-GAAP earnings per share were $7.48, including acquired R&D charges of $4.57. This compares to $7.02 in Q3 2025, which included $0.71 of acquired R&D charges. On slide 8, we quantify the effect of price, rate, and volume on revenue growth. U.S. revenue increased 34% in Q3, primarily driven by volume growth from Zepbound and Mounjaro, partially offset by a 7% decline in price. U.S. price benefited from a favorable adjustment to estimates from rebates and discounts. Excluding this adjustment, U.S. price declined 10%. Europe revenue grew 29% in constant currency, driven by sustained strong volume growth of Mounjaro. Growth also benefited from a $410 million one-time milestone payment related to Jardiance. No additional Jardiance milestone payment remains under our agreement with Boehringer Ingelheim. In Japan, revenue grew 26% in constant currency driven by Mounjaro and Kisunla.

Lucas MontarceCFO

Mounjaro posted robust volume growth as share of new patient starts increased to over 50%. In China, revenue grew 62% in constant currency driven by the uptake of Mounjaro. Mounjaro is the first medicine in China to exceed $1 billion of revenue during its first full year. In rest of the world, revenue grew 87% in constant currency driven by Mounjaro, primarily in Korea, Turkey, and Brazil. Q3 revenue was positively impacted by approximately $900 million of previously mentioned items, including milestones and changes to estimates for rebates and discounts. On slide nine, we provide an update on the performance of our key products. Within immunology, Ebglyss worldwide revenue grew 59% compared to Q3 2025. In the U.S., Ebglyss continued to gain share of new prescriptions in the specialty dermatology market and is the fastest growing medicine in atopic dermatitis.

Lucas MontarceCFO

In oncology, Jaypirca had another strong quarter as worldwide revenue increased 59% compared to Q3 2025. In the U.S., Jaypirca was the fastest growing BTK inhibitor as measured by total prescriptions. Inluriyo continued its impressive uptake in the metastatic breast cancer oral SERD market, exiting Q3 with more than 60% share of new U.S. prescriptions and 40% of U.S. total prescriptions. In neuroscience, Kisunla revenue grew 175% compared to Q3 2025. Kisunla maintained its leadership position in U.S. amyloid-targeting therapies. Diagnostic testing momentum continues to build, and the number of p-tau217 blood tests more than doubled compared to Q3 2025, translating to more people being diagnosed with Alzheimer's disease and accessing treatment. Finally, in cardiometabolic health, Mounjaro and Zepbound combined for more than $16 billion of revenue, representing $6 billion of growth compared to Q3 2025.

Lucas MontarceCFO

As seen on slide 10, total prescriptions in the U.S. incretin market grew 32% compared to Q3 2025. Oral GLP-1s and the Medicare GLP-1 Bridge Program are expanding the number of people taking incretin therapy. In the U.S., total incretin prescriptions for obesity grew 82% in Q3. Approximately six out of 10 total prescriptions and more than seven out of 10 injectable prescriptions were for a Lilly medicine. In the U.S., type 2 diabetes incretin total prescription grew 8% compared to Q3 2025, and the Lilly portfolio continues to lead here with more than 60% share of market. Outside the U.S., Lilly's portfolio again performed well. Slide 11 shows aggregate trends in international incretins, which have increased by 53% since the same period last year, as measured by IQVIA gross sales.

Lucas MontarceCFO

Lilly is strengthening its leadership position outside the U.S., gaining nearly four percentage points of share compared to Q2 2026 to reach approximately 58%. Slide 12 provides an update on the Foundayo launch. In the U.S., total prescriptions and the share of new patients continue to rise. Approximately four in 10 patients starting an oral obesity medicine choose Foundayo, and the number of new Foundayo patients in Q3 doubled from the previous quarter. We look forward to launching Foundayo in type 2 diabetes in the U.S. and expect regulatory action in Q4. Outside the U.S., Foundayo has launched in four countries and is under regulatory review in more than 40 additional countries. We continue to expect a global rollout in all major markets in 2027. On slide 13, we provide an update on year-to-date capital allocation. Moving to slide 14 is our updated 2026 financial guidance.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day